Champions Oncology director receives 37,460 options

A director's options vest in four installments through August 5, 2027, and expire on November 5, 2036.

Available on EDGAR 11/09/2026 - 04:29 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:29 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Champions Oncology, Inc. director and ten percent owner Scott R. Tobin acquired 37,460 options to purchase common stock on November 5, 2026, at an exercise price of $4.76 per share. The options vest and are exercisable over a twelve-month period, with vesting dates of November 5, 2026, February 5, 2027, May 5, 2027, and August 5, 2027, and expire November 5, 2036. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Grant/Award: 37,460 shares

Grant/Award 1 txn

Insider TOBIN SCOTT R

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase Common Stock F1	37,460	$4.76	$178K

Holdings After Transaction: Option to purchase Common Stock — 37,460 options (Direct)

Footnotes (1)

1. F1. The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively.

Key Figures

Options awarded: 37,460 options Exercise price: $4.76 per share Underlying shares: 37,460 shares +1 more

4 metrics

Options awarded 37,460 options Award reported November 5, 2026

Exercise price $4.76 per share Options to purchase common stock

Underlying shares 37,460 shares Shares underlying the options

Expiration date November 5, 2036 Option expiration

Key Terms

vesting, exercisable, exercise price

3 terms

vesting financial

"with vesting to occur on November 5, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercisable financial

"vest and are exercisable over a twelve month period"

exercise price financial

"at an exercise price of $4.76 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did CSBR director Scott R. Tobin receive?

Scott R. Tobin, a director and ten percent owner of Champions Oncology, Inc., received 37,460 options to purchase common stock on November 5, 2026, at an exercise price of $4.76 per share. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOBIN SCOTT R

(Last) (First) (Middle)

C/O CHAMPIONS ONCOLOGY, INC.

ONE UNIVERSITY PLAZA, SUITE 307

(Street)

HACKENSACK NEW JERSEY 07601

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	$4.76	11/05/2026		A		37,460		(1)	11/05/2036	Common Stock	37,460	$4.76	37,460	D

Explanation of Responses:

1. The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively.

Remarks:

	/s/ Scott R. Tobin	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)